FDA approves enhancements to Insulet's Omnipod 5 algorithm

Insulet has received clearance from the US Food and Drug Administration (FDA) for an upgraded algorithm in its Omnipod 5 automated insulin delivery (AID) system, aimed at improving blood sugar management for users.

The Omnipod 5 system works in tandem with continuous glucose monitoring (CGM) devices, including leading models from Dexcom and Abbott, to automatically deliver insulin for up to three days, helping to maintain stable glucose levels.

The newly approved algorithm allows Omnipod 5 users to set insulin target ranges between 100 mg/dL and 150 mg/dL in 10 mg/dL steps, compared with the previous 110 mg/dL to 150 mg/dL range. This adjustment is designed to provide more personalized control over insulin delivery, catering to those seeking tighter glucose management or specific target goals.

The update also ensures that users can remain in automated mode with fewer interruptions, even during extended periods of elevated glucose. Insulet stated that the algorithm enhancement is expected to improve clinical outcomes while offering greater flexibility and convenience in daily life.

Eric Benjamin, Executive Vice President and COO of Insulet, described the algorithm change as the most significant improvement to the Omnipod 5 since its 2022 launch, noting that it addresses the most requested feature enhancements from users and healthcare providers alike.

The company plans to roll out the updated Omnipod 5 algorithm in the United States in the first half of 2026.

Financially, Insulet reported $706.3 million in revenue for Q3 2025, marking a 30% increase from the same quarter in 2024. Revenue from Omnipod sales reached $699.2 million, up 31%. Analysis from GlobalData indicates that the global insulin delivery market is projected to grow at a 6% compound annual growth rate, reaching an estimated $34.68 billion by 2034, up from $19.36 billion in 2024. In 2025, Insulet held a 14.5% share of the US insulin pump and CGM market, placing it third behind Abbott at 22.5% and Dexcom at 16.2%.

Analysis: Insulet's Omnipod 5 Algorithm Update and Market Impact

The recent FDA clearance of the upgraded algorithm for Insulet's Omnipod 5 automated insulin delivery system represents a significant advancement in diabetes management. The enhanced algorithm allows for more personalized insulin delivery, catering to users seeking tighter glucose control. This modification, which adjusts target ranges from 110 mg/dL to 150 mg/dL down to 100 mg/dL to 150 mg/dL, addresses a key demand from both users and healthcare providers. By enabling more precise control, it improves the overall user experience and provides an essential tool for better blood sugar management.

This move highlights Insulet's ongoing commitment to refining its product in response to user feedback, a strategy that seems to be paying off. The company's Q3 2025 revenue growth of 30% year-over-year, largely driven by strong Omnipod sales, underscores the effectiveness of its approach. With the Omnipod 5's increasing adoption and the algorithm update poised to further improve clinical outcomes, Insulet is well-positioned to expand its footprint in the global insulin delivery market, which is projected to see significant growth over the next decade.

The upgrade also ensures that users will experience fewer disruptions during extended periods of elevated glucose, offering both improved clinical results and a more seamless experience. As the rollout of the updated algorithm is expected in early 2026, it will likely strengthen Insulet's competitive position in a rapidly growing market, solidifying its place as a key player in the insulin delivery space.

Sources:

• FDA clears Insulet’s Omnipod 5 algorithm enhancements